A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients

Table 7 MTHFR polymorphisms in literature

Author	Year	Polymorphism	n	Treatment	Tumor entity	Response (p-value)	Prognosis (p-value)	Genotypes	In P F
Ott [22]	2006	MTHFR C677T	235	neo CTx 135	AEGII/III/GC	0.14	0.14
				OP 103	AEGII/III/GC	-	0.23
Ott [23]	2011	MTHFR C677T	258	neo CTx	AEGI 114	n.s.	n.s.
					AEGII-GC 144	n.s.	n.s.
		MTHFR A1298C	258	neo CTx	AEGI 114	n.s.	n.s.
					AEGII-GC 144	n.s.	0.02	AA > CC > AC	yes
Huang [28]	2008	MTHFR C677T	116	adj CTx	GC		0.04	TT/CT > CC	0.056
Wu [49]	2006	MTHFR C677T	210	neoCTx/RCTx	AEGI 174/SCC 36	n.a.	n.s.
		MTHFR A1298C	210	neoCTx/RCTx	AEGI 174/SCC36	n.a.	0.011	AC/CC > AA	n.a.
Ruzzo [51]	2006	MTHFR C677T	175	pall CTx	GC	0.2	n.s.
Chen [48]	2010	MTHFR A1298C	16/73	pall CTx	GC	-	<0.001	AA > AC/CC	n.a.
Lu [54]	2004	MTHFR C677T	75	pall CTx	GC	0.001	-	TT > CC/CT	<0.001
Goekkurt [52]	2009	MTHFR C677T	134	pall CTx	AEG/GC	0.214	0.319
		MTHFR A1298C	134	pall CTx	AEG/GC	0.053	0.524
Goekkurt [55]	2006	MTHFR C677T	52	pall CTx	GC	0.099	n.s.
Shitara [50]	2010	MTHFR C677T	132	pall CTx	GC	n.a.	0.039	TT > CC/CT
Lee [53]	2005	MTHFR C677T	40	adj CTx	GC		0.90

neo = neoadjuvant, CTx = chemotherapy, RCTx = radiochemotherapy, OP = primarily resected, adj = adjuvant, pall = palliative, AEG = adenocarcinoma of the esophagus/esophagusgastric junction, GC = gastric cancer, n.s. = not significant, n.a. = not applied, In P F = independent prognostic factor.

ISSN: 1471-2407